Clinical study

A new molecular finding (PTPRK::RSPO3 fusion) in a serrated colorectal lesion from a person with ulcerative colitis may be relevant to understanding dysplasia and cancer pathways in IBD, and could prompt further study of...

Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.

Standardized intestinal ultrasound scoring could help non-invasively monitor Crohn’s disease activity and reduce reliance on colonoscopy for some assessments. A high-sensitivity IUS score may be useful to rule out...

Smoking and similar nicotine-product use after Crohn's surgery appears linked to higher rates of endoscopic recurrence, which may affect postoperative monitoring and secondary-prevention strategies. Patients using HNBT...

The studies identify a metabolic reason why the inflamed gut struggles to heal: inflammation reduces an enzyme (QPRT) needed for NAD+ production, starving regenerating intestinal cells of energy. That suggests...

Unaffected family members often worry about their own risk and may make dietary changes based on beliefs rather than evidence. Understanding these perceptions can help clinicians give clearer, balanced guidance about...

If validated, blood protein signatures that appear years before symptoms could help identify people at higher risk of Crohn’s disease and point to lifestyle or dietary measures that alter early biology.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...

Sarcopenia (low muscle mass) was linked with worse outcomes in Crohn’s disease and, combined with fecal calprotectin and disease behaviour, formed a score that better predicted unfavourable courses. Identifying at-risk...

People with ulcerative colitis taking etrasimod may have higher drug levels if they have certain CYP2C9 genotypes or significant liver impairment; dose adjustments could be needed to avoid increased exposure.

Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...

The study links specific foods and combined dietary patterns with higher or lower odds of ulcerative colitis, which could inform patient conversations about diet and priorities for future research.

Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...

Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.

Timing of therapies and daily behaviors may affect drug metabolism, immune activity, and symptom patterns in IBD. Considering when treatments are given could potentially improve response, reduce toxicity, and help...

This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...

Accurate measurement of physical activity matters because it’s linked to symptoms, fitness, and overall health.

Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...

Individual factors like CYP2C9 genotype and liver impairment can raise etrasimod levels. The study’s model-based dose suggestions could help personalize dosing to reduce risk of excess exposure.

The study suggests a targeted microbiome-based drug (sialidase inhibitor) may protect the mucus barrier and improve symptoms in ulcerative colitis without the broad disruption caused by antibiotics, which could be...

People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...

Identifies specific gut bacteria and fecal bilirubin metabolites that may link microbial loss to increased oxidative burden in IBD; suggests new biomarker candidates and targets for functional follow-up.

This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...

The study uses generative AI and microbiome/RNA data to search for biomarkers of intestinal fibrosis in Crohn’s disease, which could help spot scarring earlier and potentially prevent worsening complications like...

This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.

Researchers are testing whether IL-22 — a cytokine known to help repair gut and airway lining — could protect or heal GI tissues after SARS‑CoV‑2 infection. If true, this could point to therapies relevant to people with...

This funded NIH project investigates how EAEC and AIEC bacteria might drive intestinal inflammation by degrading MUC3A/MUC4 and disrupting receptor tyrosine kinase signaling—mechanisms that could underlie...

If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...

New high-resolution, multilayer imaging tools can reveal how immune cells, epithelium, and enteric nerves interact in the intestine—processes central to IBD, colorectal cancer risk, and gut-brain disorders.

Researchers are exploring whether transferring younger gut microbiomes could slow aging and prevent age-related diseases. If validated, the work could point to microbiome-based therapies that affect systemic health,...

Researchers are using a new MRI-based index (ANDI) to look for early brain changes linked to Parkinson’s disease and dementia in groups at higher risk, including people with inflammatory bowel disease. If successful, the...

A simple home test for urinary oxalate and Ox/Crea ratio could make monitoring more practical than 24-hour urine collections, helping prevent stone recurrence and allowing earlier treatment adjustments for people at...

This study suggests brain glymphatic function — a fluid-clearance system — may be altered in people with Crohn’s disease and could relate to inflammation and common neuropsychiatric symptoms like fatigue, anxiety,...

Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...

The study reports a targeted nanoparticle designed to deliver celastrol selectively to inflamed intestinal tissue and colorectal tumors, which could—if translated successfully—address limitations of oral celastrol and...

Patients with ulcerative colitis and PSC face higher risk of pouch inflammation after IPAA. The study reports fewer pouchitis events among the small group who received antibiotics or immunosuppression, which could...

IBD increases risk of osteoporosis; identifying blood proteins that predict later bone loss could help flag higher-risk patients and reveal biological links between gut inflammation and bone health.

The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...

If confirmed, a gut-derived strain of Lancefieldella parvula that rises with local inflammation could become a mucosal biomarker to help track disease severity or study inflammation mechanisms in IBD.

If intestinal ultrasound shows mild isolated hyperemia even with normal bowel wall thickness, this study found a higher chance of treatment changes, steroid use, surgery, or hospitalization within a year — information...

This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.

Fatigue is common and disabling for people with IBD; this study shows that factors beyond intestinal inflammation—especially central sensitization and psychological symptoms—explain much of fatigue. That means treating...

This study suggests heated-tobacco products (and possibly e-cigarettes) may increase the risk of endoscopic recurrence after ileocolic resection for Crohn’s disease, which could affect postoperative outcomes and...

1) People with IBD are known to have higher cardiovascular risk; this study directly assessed subclinical carotid atherosclerosis to see if plaque burden explains that risk.

Ustekinumab is already approved for moderate-to-severe Crohn's disease; this real-world study reports encouraging longer-term clinical, biological, and endoscopic outcomes up to 96 weeks and suggests good treatment...

The review links gut microbiota changes and mucosal immune responses across IBD and IgA nephropathy, suggesting that gut dysbiosis may contribute to systemic immune-driven disease.

Drug levels and how patients reach remission can differ depending on prior biologic use. For families and clinicians managing pediatric Crohn's, this can affect how infliximab dosing and monitoring are interpreted after...

The study points to a specific immune cell type (pro-inflammatory CD4+ macrophages) and altered cellular interactions in rectal tissue that are linked to perianal fistulizing Crohn's disease, which may help explain...